Area of research
Molecular Biology · Oncology
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Epigenetics and DNA Methylation, Immune Cell Function and Interaction, and Cancer Genomics and Diagnostics.
Genomic and phenotypic stability of fusion-driven pediatric sarcoma cell lines
Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer
Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time
A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection
Genome-scale pan-cancer interrogation of lncRNA dependencies using CasRx
Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma
The Caspase-Activated DNase drives inflammation and contributes to defense against viral infection
Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury
Hyperreactive B cells instruct their elimination by T cells to curb autoinflammation and lymphomagenesis
High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells
Corrigendum to “A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer” [Bioorgan. Chem. 119 (2022) 105505]
FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells
Mutual regulation of CD4+ T cells and intravascular fibrin in infections
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
eIF3 mRNA selectivity profiling reveals eIF3k as a cancer‐relevant regulator of ribosome content
An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
In vivo interrogation of regulatory genomes reveals extensive quasi-insufficiency in cancer evolution
Genomic and phenotypic stability of fusion-driven pediatric Ewing sarcoma cell lines
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment
Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD
Spatiotemporal dynamics of self-organized branching in pancreas-derived organoids
Identification of treatment‐induced vulnerabilities in pancreatic cancer patients using functional model systems
Spontaneous activity of the mitochondrial apoptosis pathway drives chromosomal defects, the appearance of micronuclei and cancer metastasis through the Caspase-Activated DNAse
Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
The OTUD6B‐LIN28B‐MYC axis determines the proliferative state in multiple myeloma
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
CCL17 Promotes Colitis-Associated Tumorigenesis Dependent on the Microbiota
Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
eIF3 mRNA selectivity profiling reveals eIF3k as a cancer-relevant regulator of ribosome content